10/24/2013

Merck, Johnson & Johnson and Sanofi recently launched open source drug development projects that "represent a sea change in the pre-competitive landscape for pharmaceutical development," writes John Wilbanks, a senior fellow at FasterCures and chief commons officer at Sage Bionetworks. The open source movement in drug discovery is being driven by massive public investment in health and biology, as well as governmental and institutional momentum to open knowledge bases for reuse and recombination, Wilbanks writes. "This level of progress would have been unthinkable just a decade ago at the height of the first genomics bubble," he writes.

Full Story:
Xconomy

Related Summaries